BENITIONSClinical Trial Intelligence

Severe Asthma, MepolizumaB and Affect: SAMBA Study

N/A Completed NCT04680611

ConditionSevere Eosinophilic Asthma, Psychological Distress, Anxiety, Depression
PhaseN/A
SponsorUniversity Hospital Southampton NHS Foundation Trust
StatusCompleted
Enrollment120 participants
Interventionsno study intervention. Patients receive standard clinical care
Start dateSep 9, 2021
Completion dateMar 26, 2025
Results postedJul 13, 2026

Summary

This is a real-life pragmatic non-randomised study to explore the impact of mepolizumab on the emotional and affective outcomes of patients with severe eosinophilic asthma and their partners. It will be conducted in two quantitative stages (Phases 1 and 2) with an additional third qualitative component (Phase 3).

Change in Emotional Composition (Using the Geneva Emotions Wheel)

Change to one year after start of treatment · score

Patients With Severe Eosinophilic Asthma Phase 20.9 score
Partners of Patients With Severe Eosinophilic Asthma Phase 20.1 score
Patients With Severe Eosinophilic Asthma Phase 20.7 score
Partners of Patients With Severe Eosinophilic Asthma Phase 20.0 score
Patients With Severe Eosinophilic Asthma Phase 20.0 score
Partners of Patients With Severe Eosinophilic Asthma Phase 20.2 score

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

All trials

This page summarises publicly available data from ClinicalTrials.gov. It is not medical advice and not investment advice. Always consult a qualified healthcare professional.